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The theory of the clonal origin of cancer states that a tumour arises from one
cell that acquires mutation(s) leading to the malignant phenotype. It is the
current belief that many of these mutations give a fitness advantage to
the mutant population allowing it to expand, eventually leading to disease.
However,mutations that lead to such a clonal expansion need not give a fitness
advantage and may in fact be neutral—or almost neutral—with respect to fit-
ness. Suchmutant clones can be eliminated or expand stochastically, leading to
a malignant phenotype (disease). Mutations in haematopoietic stem cells give
rise to diseases such as chronic myeloid leukaemia (CML) and paroxysmal
nocturnal haemoglobinuria (PNH). Although neutral drift often leads to
clonal extinction, disease is still possible, and in this case, it has important
implications both for the incidence of disease and for therapy, as it may be
more difficult to eliminate neutral mutations with therapy. We illustrate the
consequences of such dynamics, using CML and PNH as examples. These
considerations have implications for many other tumours as well.1. Introduction
Tissue homeostasis gives the impression that cell populations are constant and
hides the fact that beneath this appearance of stability, there is substantial cell turn-
over. This is the case in all epithelial tissues (skin, gut, breast) as well as in
haematopoiesis. These tissues have a similar architecture where at the root lie
tissue-specific stem cells that divide to self-renew and give rise to progeny cells
that differentiate into the various types of cells present within the tissue. As long
as the dynamic exchanges between these populations are balanced, homeostasis
ensues. Therefore, at some macroscopic timescale, the sizes of these hierarchically
organized populations, arising from the stem cell population, appear constant.
The stochastic dynamics in such stem cell populations of constant size
can conveniently be modelled by the Moran process from population genetics
[1–3], a birth–death process (figure 1). Each cell has a certain fitness that is
in our case constant. In each time step, a cell is chosen for reproduction at
random, but with probability proportional to the fitness. This cell produces
identical offspring, replacing a randomly chosen cell, which is considered to
differentiate to the next stage. Effectively, this is a death event, because that
cell leaves the stem cell compartment and cannot be selected again for repro-
duction. In this model, cell export captures the initial step in the path
towards differentiation of that cell, usually through intermediate cells known
as progenitors. Stem cells can acquire mutations, and it is possible that these
confer a higher reproductive fitness to the mutated stem cells, hence increasing
the chances that the mutant population will invade the whole stem cell compart-
ment. This leads to a so-called clone that corresponds to all the offspring of the
mutated cell divides,
wild-type cell differentiates 
mutated cell divides,
mutated cell differentiates 
wild-type cell divides,
wild-type cell differentiates 
wild-type cell divides,




Figure 1. Possible changes of the number of mutated cells in an elementary time step of the Moran process. (a) The number of mutated cells can increases by one
if a wild-type cell differentiates and a mutated cell divides. (b,c) If the same cell type is affected by cell division and differentiation, then the number of mutated
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may give a fitness disadvantage and such a clone will be elimi-
nated with a probability that increases with the population size
and the fitness disadvantage of the cell. As such, these two
extremes will induce two potential outcomes: either the
mutant population takes over completely or it undergoes
extinction. Additionally, certain mutations may not cause a
reproductive advantage, i.e. neutral mutations. This case is
also a good approximation if selection isweak, i.e. if the product
of population size and fitness differences is small [4]. Even in
this case, the potential outcomes will, in the long run, be the
same as for the two extreme cases mentioned earlier.
However, all organisms have a finite lifetime and so one
expects intermediate regimes with mixed populations. Such
mixed regimes last longest for neutral mutations when fitness
is constant [5]. Such a scenario is not a mere theoretical exercise.
Many mutations are indeed neutral [6,7] but the impact of a
mutation is cell-context-dependent. In fact, the same mutation
may be neutral in one microenvironment but exhibit a fitness
difference in another [8–10]. Fitness may also fluctuate in time
[11], reflecting changes in the environment of the cells. Here,
we do not consider this more complex scenario, but concentrate
on fixed fitness values.
There is some evidence, for example, that BCR-ABL
expression in a haematopoietic stem cell (HSC) gives no fitness
advantage to the cell while the same oncogene expressed inprogenitor cells confers to them a fitness advantage [9,10,
12–14]. Therefore, the expansion of a BCR-ABL mutant stem
cell clone could rely entirely on neutral drift. In a similar
manner, neutral drift can explain the incidence, population age
structure and spontaneous elimination of PIG-A mutant clones
[15,16], a gene required for the synthesis of glycosylphosphatidyl
inositol-linked proteins that leads to the phenotype observed
in paroxysmal nocturnal haemoglobinuria (PNH) [17–19]. In
fact, the change of the reproductive fitness of cells owing to
acquired mutations is often unrelated to their effect on the
entire organism where ‘disease’ may or may not manifest itself
as a reduction in the ‘fitness’ of the entire organism.
Let us consider the appearance of a mutation, say BCR-
ABL, that has no impact on the reproduction of the HSCs
[12–14,20]. Given that the size of the active HSC pool (i.e. the
number of HSC that are contributing to haematopoiesis) is
small (of the order of 400 cells [21,22]), one expects stochastic
effects to have a prominent impact on the clonal evolution of
the mutant population [2,23], as also observed in related sys-
tems [24]. The theory of the clonal origin of cancer tells us
that we start with one cell that arises owing to mutation [25].
How will this clone evolve in time? If the first mutant cell is
selected for export, the mutation will disappear from the
HSC pool, and only a newmutation will re-initiate such a line-
age, an unlikely event [26,27]. By contrast, if such a cell is
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very unlikely scenario). As the population of mutant cells
increases, the probability that one of them is selected either
for reproduction or export also increases. What would be the
rate of expansion of such a population? This process is relevant,
because persistence of a ‘neutral’ clone can maintain disease in
the absence of therapy that can specifically kill such cells
[10,19,28]. Moreover, such a process may in part explain why
in many tumours, the cancer stem cell population is small,
while in others, many of the cancer cells have tumour initiating
capability [29,30]. In the following, we provide a mathematical
description of such a process and show how stochastic
simulations (see appendix) confirm such a behaviour.Interface
10:201208102. Stem cell dynamics
Consider a population of constant size N, where cells repli-
cate and differentiate in discrete time steps. In each time
step, a cell is selected for reproduction, proportional to fitness
and divides symmetrically, producing identical offspring. In
the neutral case with j mutant cells, the probability that we
select one of them for reproduction is j/N, while with prob-
ability (N2 j )/N, we select a normal cell for reproduction;
see table 1 for an overview of the notation. If the mutant
cells have a fitness r, the probability of selection is rj/(rj þ
N2 j ). If r . 1, the mutant has a higher relative fitness com-
pared with the wild-type. If r , 1, the mutant has a lower
relative fitness, whereas if r ¼ 1, mutant and normal cells
have the same fitness. Given that the total population of cells
remains constant, then with each reproduction event, we
choose a cell for export at random—a typical assumption is
that this celldifferentiatesduringcelldivision andcannotbe con-
sidered as a primitive stem cell anymore. With probability j/N,
we choose a mutant cell for export, whereas with probability
(N2 j)/N, we choose a normal cell for export.When the process
is repeated N times, on average, each cell would have had one
chance to reproduce. This natural timescale of the process is
often referred to as generation. For example, in the case of the
active HSC pool, we have N ¼ 400, and each HSC reproduces,
on average, about once per year [21,22]. Therefore, when 400
selection–reproduction–export events have occurred, a year
will have passed and, on average, each cell would have
reproduced once (for neutral mutations).
Note that we have excluded the possibility that a cell
divides asymmetrically and produces one differentiated
daughter cell and one daughter cell identical to the parent
cell. The presence of such asymmetric stem cell divisions
would slow down the dynamics between different stem
cells. If all cell divisions would be asymmetric, the number
of stem cells of each type would remain constant, with no
room for expansion or extinction of mutated stem cells
within the stem cell pool.2.1. Moran process
The neutral Moran process is a birth–death process with















ð2:1Þ(figure 1). Let us first address the probability that the mutant
clone goes extinct. For a neutral mutation, this probability is
given by 12N21 in the long run. For short times, we can add
the different paths that lead to extinction. The number of such
possible paths increases rapidly with t: there is only one path
to extinction in one time step or two time steps, there are
two paths to extinction in three time steps, and there
are four paths to extinction in four time steps. For example,
the probability that the mutant cells go extinct within t ¼ 4
time steps is given by
M41!0 ¼ T1!0
þ T1!1T1!0
þ T1!1T1!1T1!0 þ T1!2T2!1T1!0
þ T1!1T1!1T1!1T1!0 þ T1!1T1!2T2!1T1!0
þ T1!2T2!2T2!1T1!0 þ T1!2T2!1T1!1T1!0; ð2:2Þ
where we have introduced the transition matrix after t time
steps, Mi!j
t ¼ (Ti!j)t for notational convenience. Let us
now approximate M1!0
t for large N. Because jN, we
have Tj!j+1 ¼ j=NððN  jÞ=NÞ  1=N and T j!j ¼ 1 2j=N
ððN  jÞ=NÞ  1 ð2=NÞ  1 for jN. The probability to
stay in a state is approximately 1, but the probability
to move to an adjacent state is close to zero. Thus, we can
approximate M1!0
t by considering the paths that have up to
only a certain number of transitions between states. Taking
into account only transitions in which the number of mutants


















where the approximation is valid for large N. For tN, the
result can be approximated by t/N. We can improve this
approximation by taking into account also those paths in
which we reach extinction with up to three transitions between










ðk þ 1ÞðT1!1ÞkðT2!2Þj; ð2:4Þ
Going one step further, we could also include the paths invol-
ving five transitions, which would lead to two additional


















ðk þ 1ÞðT1!1Þkð jþ 1ÞðT2!2ÞjðT3!3Þl:
Note that there are two classes of paths, one in which the
state with two mutants is entered and left twice (first
line) and one in which the state with three mutants is rea-
ched (second line). However, figure 2 illustrates that this
approximation is only a marginal improvement over the






















Figure 2. Time-dependent probability of extinction. We show the analytical approximations based on equations (2.3)– (2.5) and simulations for N ¼ 100 (circles
with error bars given by the standard error of the binomial distribution) and for N ¼ 10 000 (line). Time has been re-scaled to generations, one generation consists
of N time steps. For the simulations, the population size has a marginal influence only for N . 100. While the approximation with three transitions, equation (2.4)
is a significant improvement over the approximation with only one transition, equation (2.3), taking into account five transitions (equation (2.5)) does not improve
the approximation much further. This indicates that for a better approximation for long times, many terms have to be taken into account (simulations averaged over
100 realizations). (Online version in colour.)
Table 1. Overview of symbols used.
symbol description
N population size (ﬁxed)
r relative ﬁtness of the mutated cell type
t time step, N time steps are one generation
j,k number of mutants
Tj!k probability to go from j to k in one time step
Mj!k
t probability to go from j to k in t time steps
ct number of mutants at time t conditioned upon no
extinction, starting from 1
kctl expected number of mutants at time t conditioned
upon no extinction, starting from 1






 on December 10, 2012rsif.royalsocietypublishing.orgDownloaded from that to derive a better approximation of the time-dependent
extinction probability for larger times, we would need to con-
sider a very large number of terms. A similar effect is found
for the Wright–Fisher process [31,32].
We are also interested in the conditional average number
of mutants c after t time steps given that the mutants do not
go extinct, kctl. This can be obtained by averaging only over










For the numerator, we have at t ¼ 1
XN
k¼1
M11!k k ¼ T1!1  1þ T1!2  2 ¼ 1: ð2:6Þ
Thus, the average number of mutants does not change in
the first time step. Because the transition probabilities
are constant in time, it does not change in the second time
step either. This can be iterated to see that the average
number of mutants remains constant (this can also be seen
directly from the transition probabilities: for neutral pro-
cesses, Ti!i 2 1 ¼ Ti!i þ 1 and thus, the average cannot





1!kk ¼ 1. In the denominator
of equation (2.5), the transition probabilities out of state 1
are normalized. In other words, after t time steps, the pro-
cess has to end up somewhere between 0 and N. Thus, the
probabilities to end up in a state k. 0 or in state k ¼ 0




1!k ¼ 1Mt1!0. The term
M1!0






Figure 3 shows that this linear increase is a good approxi-
mation not only for small t, but for the first fewgenerations. This is consistent with the arguments above.
Because the conditional fixation time of a single neutral
mutant is N2 1 generations [33–35], we expect that after
2N generations, the conditional number of mutants is already
close to N, as seen in our simulations for N ¼ 10 in figure 3
(see appendix for an explanation of the simulations).











Again, we apply the same approximation as above and consider
only those terms that are based on at most a single transition




2  Tt1!1  1þ T1!2
Xt1
j¼0




























Figure 3. The average fraction of mutants conditioned upon no extinction. Our analytical approximation equation (2.7) is good for up to N/4 generations, in contrast
to the approximations for the probability of extinction, which holds only for a single generation (cf. figure 2). For longer times, the fraction of mutants increases at a
slower rate, reaching the maximum N after approximately 2N generations, which is consistent with the average conditional fixation time of the neutral mutants. The
distribution becomes broader with time, but narrows again when almost all realizations have reached fixation, as illustrated for the case of N ¼ 10 (error bars






 on December 10, 2012rsif.royalsocietypublishing.orgDownloaded from Note that this approximation neglects transitions to states
k. 2. The next term, in which two transitions are allowed,














3!3  9: ð2:10Þ
However, including this term leads only to a minor improve-
ment of the approximation. Next, we approximate equation





2  1þ 2t2N, and find














Thus, the leading dependence in t of our approximation is
linear, in accord with the numerical results shown in figure 3.
Note, however, that our approximation for the error holds
quantitatively for very short times only. We note that the limit
of the approximation is not the Taylor expansion for large N,
but the assumption that only few transitions occur. For more
precise approximations, a large number of such terms would
have to be taken into account.3. Discussion
The results of our simulations and mathematical analysis
have implications for the incidence of acquired HSC dis-
orders. Given that a population with a neutral mutation (or
a mutation that confers a very small change in fitness,
N(r2 1)1), on average increases by only one cell per year,
then we can conclude that in a disease such as PNH, theoriginal mutation in PIG-A must occur early in life for the
clone to reach a threshold compatible with disease (e.g. 10%
of the stem cell population being mutated [36]), given that
the average age of patients with this disease is in the fourth
or fifth decade of life. Of course, this is the average and in
principle, growth of the population can be significantly
faster—or slower—owing to stochastic effects alone [2]. The
other option would be to imply some sort of fitness advantage
for the clone either owing to an intrinsic effect, as for instance
a second mutation, such as HMGA2 [18,37], or extrinsic effect
such as an immune-mediated attack on normal HSC as pro-
posed by Luzzatto et al. [38]. As discussed elsewhere [26],
the probability of a second mutation in the same cell that
gives it a fitness advantage is small, and perhaps this is the
reason why to date, only a couple of patients have been
described with such a second mutation [18]. On the other
hand, a fitness advantage could explain instances where
the clone is very large, while neutral drift would explain the
majority of situations where the clone is large enough to
cause disease [19].
In the case of CML, the incidence is almost invariably
in people beyond the second or third decade of life.
The latent period between the appearance of the Philadelphia
chromosome [39] in a HSC and diagnosis is often consi-
dered to be in the range of 3–5 years. Therefore, it appears
that most mutations leading to the Ph’ chromosome occur
later in life, presumably because the probability of a chromo-
somal recombination event leading to such a specific
translocation is smaller than the probability of a mutation
in PIG-A where a variety of mutations can inactivate the
gene [40–42].
Our modelling can also explain an apparent paradox:
many mutations in PIG-A inactivate the gene but clinically
significant PNH is rare. CML is a significantly more
common disorder compared with PNH (by at least one
order of magnitude), despite the fact that it is triggered by






 on December 10, 2012rsif.royalsocietypublishing.orgDownloaded from mutated cell. Neutral drift means that clonal expansion, in
general will be slow and this is enough to explain why
PNH is rare. If BCR-ABL expression does not give a fitness
advantage, why is the incidence of the disease significantly
more common? The difference lies in the fact that BCR-ABL
expression does give a fitness advantage to cells downstream
of the HSC owing to enhanced self-renewal of the cells
[10,27,28,43], leading to their expansion with myeloprolifera-
tion and ultimately disease. Hence, and although the
population of CML stem cells is small, the disease is driven
by progenitor cells that rapidly expand in number and essen-
tially may invade haematopoiesis leading to disease. If CML
stem cells would instead have an increased propensity to
differentiate, the clone would die out faster, because
increased differentiation implies loss of these cells from the
stem cell compartment.
An alternative possibility would be that chromosomal
instability induced by BCR-ABL expression [44,45] would
result in the accumulation of additional mutations that can
accelerate the development of disease. This line of reasoning
implies that BCR-ABL expression alone may not be enough to
explain the initial development of chronic-phase CML. In our
view, this hypothesis would not be in keeping with the
results of animal experiments where a disease phenotype
similar to chronic phase CML is induced within weeks of
the introduction of BCR-ABL expressing HSC in immuno-
deficient animals [46]. However, even in this case, the
affected cells would need a fitness advantage to lead to an
early onset of the disease compared with the neutral case.
Note that our model does not capture late stages of the
disease, where additional mutations may lead to different
phenotypes. In addition, in these stages, the assumption of
a constant population size may break down.
CML can be well controlled, and haematopoiesis returns
to normal because at the level of the stem cell pool, the
majority of cells are normal [47] and haematopoiesis
recovers once the impact of BCR-ABL on cells is blocked
by tyrosine kinase inhibitors such as imatinib. By contrast,
expansion of the clone in PNH is less likely, because PIG-
A does not give a fitness advantage either to HSC or
progenitor cells. Moreover, as shown earlier, when PNH is
diagnosed, reflecting the (less likely) success of clonal
expansion, the clone size at the level of the stem cell pool
will in general be sizeable, which makes elimination of the
clone extremely difficult—except for stochastic extinction
[17,19], only a bone marrow transplant will eliminate the
clone and cure the disease. Therapy with eculizumab, a
monoclonal antibody that inhibits the C5 complement com-
ponent and prevents intravascular haemolysis, has no
impact on clone size in this disease, and therefore is not
curative [48,49].
As can be seen from this analysis, neutral mutations have
many flavours with implications for a variety of disorders
that ostensibly arise within the same cell. As in real estate,
location is everything. A neutral mutation in some cells
may provide a fitness advantage to their progeny cells
(BCR-ABL) that can also make them amenable to therapy.
A neutral mutation may be an innocuous passenger but at
times leads to a disease that can be as resistant as any other
with respect to therapy. Small may not be cute—it may be
stubborn, even lethal.
These evolutionary considerations have potential impli-
cations for other clonal disorders as well. Genomicsequencing of tumours identifies many mutated genes. The
majority of these mutated genes are thought to be ‘passen-
gers’ [50], perhaps implying that they are not important for
tumour growth or survival. Such nomenclature may be mis-
leading, as potentially important mutations that are relevant
or even critical for the tumour may be ignored.Appendix
A.1. Branching process
To connect our work to previous papers based on branching
processes, we can also consider the dynamics of mutant cells
as a branching process [51–53]. As a timescale, we consider
a single cell division. With probability p ¼ 1/N, a particular
cell produces two offspring cells. With the same probability
p, it is exported and lost from the stem cell pool (this is
equivalent to asymmetric cell division). Finally, with prob-
ability 12 2p, it remains unaffected (and thus can be
considered as having a single offspring), the equivalent of
self-renewal. Thus, the average number of offspring at time
t is given by mt ¼ 0  pþ 1  ð1 2pÞ þ 2  p ¼ 1, which
implies a constant average number of mutated stem cells.
Owing to this restriction, we are dealing with a critical
branching process [52]. This implies that the mutated stem
cells eventually go extinct with probability one. However,
because we consider a population of size N, once the
mutated cells hit this threshold (i.e. they invade the popu-
lation) they cannot go extinct anymore. But such a
statement is not necessarily helpful in our context, because
extinction may take longer than the lifetime of
the associated individual. Because extinction is likely, the
fact that the average number of mutated stem cells is
constant implies large fluctuations of the process [2,52].
The variance in the number of offspring is given by
s2 ¼ ð02  pþ 12  ð1 2pÞ þ 22  pÞ m2t ¼ 2p. From the var-
iance, we can obtain the scaling of the expected number of
mutated cells ct given that mt ¼ 1, ct  s2t=2 ¼ t=N [52].
This scaling holds for large t. Thus, the expected number
of mutated stem cells given that they do not go extinct
grow by one per generation. This has also been observed
in a Moran model of stem cell dynamics [28]. Next, we
show that the result can also be obtained directly from the
Moran model when the population size is not too small.
This illustrates that the conditional growth rate of 1 per
generation is valid even for short time t.A.2. Computer simulations
For the computer simulations, the Moran process was
implemented as follows: the system is characterized by the
number of mutants j. In each time step, the probabilities to
transit to j+ 1 or to stay in j are calculated based on j, N
and r, see §2. Then, a single pseudorandom number is gener-
ated that determines which of the three possible transitions is
realized (transfer to j+ 1 or stay in j ). The procedure is then
continued in the next state. For the time-dependent extinction
probability, the fraction of runs leading to the extinction of all
mutants until a certain time is computed (figure 2). For the
number of cells given no extinction, as shown in figure 3,
only those runs in which extinction did not occur so far
are considered.
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